Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream
NCT ID: NCT00189306
Last Updated: 2010-08-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
169 participants
INTERVENTIONAL
2001-03-31
2007-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
NCT00129519
A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma
NCT00189241
Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer
NCT00066872
A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base
NCT00463359
Basal Cell Carcinoma Chemoprevention Trial
NCT05212246
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aldara
Aldara (imiquimod) cream 5% applied 7 times per week for 6 weeks
Imiquimod 5% cream
Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Imiquimod 5% cream
Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Minimum tumor size 0.5 cm2 and maximum diameter of 2.0 cm
Exclusion Criteria
* Cannot have recent use of topical steroids or retinoids in the treatment area.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Graceway Pharmaceuticals, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Graceway Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jim Lee, Dr.
Role: STUDY_DIRECTOR
Graceway Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Centre, Concord Hospital
Concord, New South Wales, Australia
Prince of Wales Hospital
Randwick, New South Wales, Australia
Skin Centre
Benowa, Queensland, Australia
South East Dermatology Centre
Carina Heights, Queensland, Australia
105 Fulham Road
Gulliver, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Flinders Medical Center
Bedford Park, South Australia, Australia
Queen Elizabeth Hospital
Woodville, South Australia, Australia
Western Hospital
Footscray, Victoria, Australia
Austin & Repartriation Hospital
Heidelburg, Victoria, Australia
Freemantle Dermatology
Fremantle, Western Australia, Australia
158 South Terrace
Perth, Western Australia, Australia
Subiaco Clinic
Subiaco, Western Australia, Australia
103A Mountain Road
Epsom, Auckland, New Zealand
Birthcare Building
Parnell, Auckland, New Zealand
Colombo Mansions
Christchurch, , New Zealand
Dermatology Practice
Christchurch, , New Zealand
Skin Institute Limited
Takapuna, , New Zealand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Quirk C, Gebauer K, Owens M, Stampone P. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol. 2006 Nov;47(4):258-65. doi: 10.1111/j.1440-0960.2006.00313.x.
Quirk C, Gebauer K, De'Ambrosis B, Slade HB, Meng TC. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis. 2010 Jun;85(6):318-24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1413-IMIQ
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.